Back

Impact of sodium-glucose co-transporter inhibitors in mortality and decongestion in cardiac amyloidosis: A systematic review and meta-analysis

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Myocardial disease and valvular heart disease: miscellany Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Mrs Christiane Espirito Santo

Instituto do Coracao FMUSP, Sao Paulo (Brazil)

6 More presentations in this session

Presentation thumbnail
Radiofrequency septal ablation as a therapeutic option in refractory obstructive hypertrophic cardiomyopathy to myectomy: a case series
Doctor F. De Brito Fortuna (Sao Paulo, BR)
Abstract Slides Video
Presentation thumbnail
Mavacamten real-world experience: insights from the Dutch HCM Network.
Doctor P. Zwetsloot (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Temporal and demographic disparities in cardiogenic shock mortality among patients with ischemic cardiomyopathy in the United States, 1999-2020
Doctor A. Zafar (Wigan, GB)
Abstract Slides Video
Presentation thumbnail
Cardiac mechanics in primary mitral regurgitation: effect of exercise in cardiac strain and hemodynamic parameters
Doctor I. Dimitroglou (Athens, GR)
Abstract Slides Video
Presentation thumbnail
The prognostic value of small psoas muscle area in patients undergoing mitral edge-to-edge repair
Doctor R. Shigeno (Okayama, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Myocardial disease and valvular heart disease: miscellany

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
New horizons in transthyretin cardiac amyloidosis therapy: A systematic review and meta-analysis of sodium-glucose cotransporter 2 inhibitors efficacy
thumbnail
Congress Presentation
Using dapagliflozin to reduce NT-proBNP and improve symptom in transthyretin cardiac amyloidosis - a series of n-of-1 trials pilot study
thumbnail
Congress Presentation
SGLT2 inhibitors improve cardiovascular clinical outcomes in patients undergoing anthracycline chemotherapy: a systematic review and meta-analysis of 13,333 patients.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources